Talk:Johnson & Johnson/Archives/2022
 | This page is an archive of past discussions. Do not edit the contents of this page. If you wish to start a new discussion or revive an old one, please do so on the current talk page. |
2022 Factual Updates
Hi! I'm posting here on behalf of Johnson & Johnson, a company I have declared my COI. I noticed some inaccuracies and omissions in the Infobox, Lead, and Corporate governance sections. Below are the suggested improvements to each part of the article. @Grand'mere Eugene: Would you be open to making these minor updates? Let me know if there are any questions!--Chefmikesf (talk) 22:01, 25 May 2022 (UTC)
Done. Chefmikesf, The article is so large it takes forever to save the document, and it's probably longer than most of our readers would plow through. Did we discuss before splitting off the Recalls and litigation section? That would be a logical offspring, and it's long enough to stand alone. Let me know what you think—there may be another section that would be better? Grand'mere Eugene (talk) 00:20, 26 May 2022 (UTC)
- Grand'mere Eugene Thanks for reminding me about this. Let me re-read the article over the weekend and gather some thoughts on the topic. Hope you have a great holiday weekend!--Chefmikesf (talk) 18:15, 26 May 2022 (UTC)
2022 Factual Updates
|
|---|
|
1. Reason and Request: The last sentence in the lead paragraph is inaccurate.
Proposed Lead Paragraph sentence update The company announced in November 2021 that it would split into two publicly traded companies: one focused on consumer products and the other on pharmaceuticals and medical technologies. 2. Reason and Request: Please update the Corporate governance section with the additions in Proposed Corporate governance content. The Corporate governance section is missing key members of the Board of Directors and Executive Leadership Team. The proposed version includes current information for the company. Please see the references used on the article. These references include the missing members of each respective committee. Proposed Corporate governance content The current members of the board of directors of Johnson & Johnson for 2022 are: Mary C. Beckerle; D Scott Davis; Ian E. L. Davis; Jennifer A Doudna; Alex Gorsky; Marillyn A. Hewson; Hubert Joly; Mark B. McClellan; Anne M. Mulcahy; A. Eugene Washinton; Mark A. Weinberger; Nadja Y. West; Ronald A. Williams; Darius Adamczyk[1] The current members of the Executive Committee of Johnson & Johnson are: Joaquin Duato; Vanessa Broadhurst; Peter Fasolo; William N. Hait; Mathai Mammen; Ashley McEvoy; Thibaut Mongon; James Swanson; Jennifer Taubert; Michael Ullman; Kathy Wengel; Joseph J. Wolk[2] On January 3, 2022, Joaquin Duato, became Chief Executive Officer. Alex Gorsky remains Executive Chairman.[3][4] 3. Reason and Request: The Infobox section has inaccuracies and is missing key content. Please consider replacing each section of the Infobox with the proposed replacement. Alex Gorsky is the Chairman. Joaquin Duato is the CEO. Paul Stoffels retired. Update Industry | industry = [[Pharmaceutical industry|Pharmaceutical]]<br />[[Medical Technology]]<br />[[Consumer products|Consumer Healthcare]] Update Key People | key_people = {{Unbulleted list | key_people = {{Unbulleted list | [[Alex Gorsky]] {{small| ([[Chairman]])}}<ref>{{cite web |title=Alex Gorsky |url=https://www.jnj.com/leadership/alex-gorsky |access-date=10 July 2020 |publisher=Johnson & Johnson |archive-url= https://web.archive.org/web/20200615213227/https://www.jnj.com/leadership/alex-gorsky |archive-date=15 June 2020 |url-status=live}}</ref> | Joaquin Duato{{small| ([[Chief executive officer|CEO]])}}<ref>{{Cite web|title=Joaquin Duato|url=https://www.jnj.com/leadership/joaquin-duato|access-date=2020-07-09|website=Content Lab U.S.|language=en}}</ref> }} References
|